These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24780451)

  • 1. Diabetic kidney disease: an ACEI (or an ARB) in the hole.
    Yee J
    Adv Chronic Kidney Dis; 2014 May; 21(3):251-5. PubMed ID: 24780451
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination of ACEI and ARB therapy for heart failure].
    Nishikimi T; Matsuoka H
    Nihon Rinsho; 2007 May; 65 Suppl 5():140-4. PubMed ID: 17569311
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation.
    Morath C; Schmied B; Mehrabi A; Weitz J; Schmidt J; Werner J; Buchler MW; Morcos M; Nawroth PP; Schwenger V; Doehler B; Opelz G; Zeier M
    Clin Transplant; 2009 Dec; 23 Suppl 21():33-6. PubMed ID: 19930314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS blockers: Does sex matter? Re: Sex differences in the effectiveness of ARB and ACEI in patients with congestive heart failure - A population study: Marie Hudson et al. European Journal of Heart Failure 9 (2007) 602-609.
    Strauss MH; Hall A
    Eur J Heart Fail; 2007 Sep; 9(9):963-4; author reply 964. PubMed ID: 17669685
    [No Abstract]   [Full Text] [Related]  

  • 5. ACEI and ARB may also benefit CHF through immune system modulation (down-regulation of immune system).
    Fett JD
    Int J Cardiol; 2005 Aug; 103(1):107. PubMed ID: 16061132
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal management of chronic heart failure in patients with chronic kidney disease.
    Zachariah D; Kalra PA; Kalra PR
    J Ren Care; 2009 Mar; 35(1):2-10. PubMed ID: 19200271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage IV chronic kidney disease.
    Hirsch S
    N Engl J Med; 2010 May; 362(20):1942-3; author reply 1943. PubMed ID: 20496469
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies.
    Muneer K; Nair A
    Indian Heart J; 2017; 69(3):371-374. PubMed ID: 28648436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL; Townsend RR
    J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: new therapeutic world beyond blood pressure reduction.
    Nakao N; Sakai M; Fujimori A; Fukagawa M
    Kidney Int; 2005 Sep; 68(3):1375-6. PubMed ID: 16105086
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure.
    Brackbill ML; Bashaw-Keaton R; Sytsma CS
    Am J Manag Care; 2007 Oct; 13(10):568-70. PubMed ID: 17927461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination therapy with ARB for heart failure].
    Sakata Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():123-7. PubMed ID: 17569310
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease.
    Kolesnyk I; Struijk DG; Dekker FW; Krediet RT
    Neth J Med; 2010 Jan; 68(1):15-23. PubMed ID: 20103817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.
    Opelz G; Zeier M; Laux G; Morath C; Döhler B
    J Am Soc Nephrol; 2006 Nov; 17(11):3257-62. PubMed ID: 17035607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are renin-angiotensin-aldosterone system inhibitors lifesaving in chronic kidney disease?
    Damman K; Lambers-Heerspink HJ
    J Am Coll Cardiol; 2014 Feb; 63(7):659-660. PubMed ID: 24269361
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
    Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.